These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6094423)

  • 1. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers.
    Phillpotts RJ; Higgins PG; Willman JS; Tyrrell DA; Lenox-Smith I
    J Antimicrob Chemother; 1984 Oct; 14(4):403-9. PubMed ID: 6094423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers.
    Al-Nakib W; Higgins PG; Barrow I; Tyrrell DA; Lenox-Smith I; Ishitsuka H
    J Antimicrob Chemother; 1987 Dec; 20(6):887-92. PubMed ID: 3326874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.
    Ninomiya Y; Shimma N; Ishitsuka H
    Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of oral 4',6-dichloroflavan to protect against rhinovirus infection in man.
    Phillpotts RJ; Wallace J; Tyrrell DA; Freestone DS; Shepherd WM
    Arch Virol; 1983; 75(1-2):115-21. PubMed ID: 6338868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410.
    Ishitsuka H; Ninomiya YT; Ohsawa C; Fujiu M; Suhara Y
    Antimicrob Agents Chemother; 1982 Oct; 22(4):617-21. PubMed ID: 6295261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410.
    Yasin SR; al-Nakib W; Tyrrell DA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):963-6. PubMed ID: 2168152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.
    Ninomiya Y; Ohsawa C; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
    Virology; 1984 Apr; 134(2):269-76. PubMed ID: 6100571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of intranasally administered 4', 6-dichloroflavan to protect against rhinovirus infection in man.
    Al-Nakib W; Willman J; Higgins PG; Tyrrell DA; Shepherd WM; Freestone DS
    Arch Virol; 1987; 92(3-4):255-60. PubMed ID: 3545152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of rhinovirus resistant to an antiviral chalcone.
    Ahmad AL; Dowsett AB; Tyrrell DA
    Antiviral Res; 1987 Aug; 8(1):27-39. PubMed ID: 2825590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhinovirus colds.
    Phillpotts RJ; Tyrrell DA
    Br Med Bull; 1985 Oct; 41(4):386-90. PubMed ID: 2996687
    [No Abstract]   [Full Text] [Related]  

  • 11. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837).
    al-Nakib W; Higgins PG; Barrow GI; Tyrrell DA; Andries K; Vanden Bussche G; Taylor N; Janssen PA
    Antimicrob Agents Chemother; 1989 Apr; 33(4):522-5. PubMed ID: 2543283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime.
    Ninomiya Y; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
    Antimicrob Agents Chemother; 1985 Apr; 27(4):595-9. PubMed ID: 2988431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of drug resistance to new antirhinovirus agents.
    Ishitsuka H; Ninomiya Y; Suhara Y
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():11-8. PubMed ID: 3025150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2.
    Phillpotts RJ; Scott GM; Higgins PG; Wallace J; Tyrrell DA; Gauci CL
    Antiviral Res; 1983 Aug; 3(2):121-36. PubMed ID: 6312877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical enviroxime against rhinovirus infection.
    Levandowski RA; Pachucki CT; Rubenis M; Jackson GG
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1004-7. PubMed ID: 6297380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers.
    Hayden FG; Turner RB; Gwaltney JM; Chi-Burris K; Gersten M; Hsyu P; Patick AK; Smith GJ; Zalman LS
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3907-16. PubMed ID: 14638501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled trial of enviroxime against natural rhinovirus infections in a community.
    Miller FD; Monto AS; DeLong DC; Exelby A; Bryan ER; Srivastava S
    Antimicrob Agents Chemother; 1985 Jan; 27(1):102-6. PubMed ID: 2984980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhespiridinchalcone].
    Weindorf N; Schultz-Ehrenburg U
    Z Hautkr; 1987 Jan; 62(1):28-38. PubMed ID: 3554800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral activity of flavones and flavans.
    Selway JW
    Prog Clin Biol Res; 1986; 213():521-36. PubMed ID: 3012583
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytoprotective effect of sofalcone in the rat gastric mucosa.
    Isobe Y; Hirose H; Muramatsu M; Aihara H
    Arzneimittelforschung; 1985; 35(1):138-41. PubMed ID: 3857044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.